Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin in early COVID-19
NCT04492254Phase 3Terminated
- Sponsor
- Thrombosis Research Institute
- Start
- Oct 2020
- Primary completion
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of enoxaparin in coronavirus disease 2019 (COVID-19), sponsored by Thrombosis Research Institute. Started Oct 2020; status: terminated.
02
Drugs
enoxaparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04492254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04492254.